Our partner is a publicly traded, clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies. Their next generation technology and robust and compelling pipeline is simply unmatched in the space. The company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary product platform.

This critical hire led and grew an established team and drove the success of this company. They led process technology and developed sustainable platforms. They defined, refined, and drove MSAT strategy, and developed scalable commercial manufacturing processes. They also developed best practices in identifying, evaluating, selecting, and managing Contract Manufacturing Organizations.